                         SEQUENCE LISTING

<110>  Mayo Foundation for Medical Education and Research
 
<120>  TARGETING PD-L1 ON TUMOR CELLS

<130>  07039-1549WO1

<150>  US 62/338,466
<151>  2016-05-18

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  469
<212>  DNA
<213>  Mus musculus

<400>  1
ctaatacgac tcactatagg gcaagcagtg gtatcaacgc agagtacatg ggggaaatac       60

accagaccag catgggcatc aagatggaga cacattctca ggtctttgta tacatgttgc      120

tgtggttgtc tggtgttgaa ggagacattg tgatgaccca gtctcacaaa ttcatgtcca      180

catcaatagg agacagagtc agcatcacct gcaaggccag tcaggatgtg ggtactggtg      240

tagcctggta tcaacagaga ccaggacaat ctcctaaatt actgatttac tggtcatcca      300

cccggcacac tggagtccct gatcgcttca caggcagtgg atctgggaca gatttcactc      360

tcaccattag ccatgtgcag tctgaagact tggcagatta tttctgtcaa caatatagta      420

gttatcctct gtacacattc ggagggggga ccaagctgga aataaacgg                  469


<210>  2
<211>  560
<212>  DNA
<213>  Mus musculus

<400>  2
ctaatacgac tcactatagg gcaagcagtg gtatcaacgc agagtacatg gggacctatg       60

atcagtgtcc tctccacagt ctctgaagac actgactcta accatgggat ggagatggat      120

ctttcttttc ctcctgtcag ggactgcagg tgtccattgc caggttcaac tgcagcagtc      180

tggacctgag ctggtgaagc ctggggcttt agtgaagata tcctgcaagg cctctggtta      240

caccttcgca ggctacgata taaactggct gaaacagagg cctggacagg gacttgagtg      300

gattggatgg atttttcctg gggatggtag tactgaatac gatgaaaaat tcaagggcaa      360

ggccacactc actgcagaca aatcctccag cacggcctac atgcagctca gcagcctgac      420

ttctgagaac tctgcagtct atttctgtgc ggtgggatcc tacggtagtg cgcgttcttt      480

tgtttactgg ggccaaggga ctctggtcac tgtctctgca gccaaaacga cacccccatc      540

tgtctatcca ctggcccctg                                                  560


<210>  3
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  synthetic primer

<400>  3
ttccaggttc cactggtgac                                                   20


<210>  4
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  synthetic primer

<400>  4
gcggccgctt cgggtgctgg gcac                                              24


<210>  5
<211>  1592
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  bispecific T-cell engager with single-chain antibody recognition 
       domains for PD-L1 and mouse CD3

<400>  5
ccttaggcgc gccaccatgg agacagacac actcctgcta tgggtactgc tgctctgggt       60

tccaggttcc actggtgacg acatccaaat gacccagagt ccatctagtc tgtctgcttc      120

ggtaggtgat agggtcacta ttacttgcag ggcctcccag gacgtgtcaa ctgcagtggc      180

ttggtaccaa cagaagcccg ggaaagctcc caaactgctg atctactccg ccagctttct      240

gtattccgga gttccgtcta gattttccgg atcaggaagc ggcacggatt tcacactcac      300

aataagcagc ctacaaccag aggacttcgc aacctactat tgtcaacagt acctgtacca      360

tccagccacc tttgggcagg gcaccaaggt ggaaatcaag cgcggtggtg gtggatcagg      420

tggaggcgga agtggaggtg gcggatccga agttcagctt gtcgagtccg gtggcggcct      480

ggttcagcct ggtgggtctt tgcgtctgtc atgcgccgcc tctggtttca ccttttcaga      540

ctcttggatc cactgggtga gacaggcccc aggaaagggt cttgagtggg ttgcatggat      600

tagcccctac ggcggcagta catattacgc ggatagcgtg aaagggaggt ttaccatcag      660

cgcagacacg tcgaagaaca ccgcatacct ccagatgaat tccctccgag ccgaagatac      720

cgccgtgtac tattgtgctc gccggcattg gcctggcggc ttcgattatt ggggacaggg      780

aactctagta acagtgtcgg ccctcagcag cggcggcggc ggcagcgagg tgcagctggt      840

ggagtctggg ggaggcttgg tgcagcctgg aaagtccctg aaactctcct gtgaggcctc      900

tggattcacc ttcagcggct atggcatgca ctgggtccgc caggctccag ggagggggct      960

ggagtcggtc gcatacatta ctagtagtag tattaatatc aaatatgctg acgctgtgaa     1020

aggccggttc accgtctcca gagacaatgc caagaactta ctgtttctac aaatgaacat     1080

tctcaagtct gaggacacag ccatgtacta ctgtgcaaga ttcgactggg acaaaaatta     1140

ctggggccaa ggaaccatgg tcaccgtctc cagcgccggc ggcggcggca gcggcggcgg     1200

cggcagcggc ggcggcggca gcgacatcca gatgacccag tctccatcat cactgcctgc     1260

ctccctggga gacagagtca ctatcaattg tcaggccagt caggacatta gcaattattt     1320

aaactggtac cagcagaaac cagggaaagc tcctaagctc ctgatctatt atacaaataa     1380

attggcagat ggagtcccat caaggttcag tggcagtggt tctgggagag attcttcttt     1440

cactatcagc agcctggaat ccgaagatat tggatcttat tactgtcaac agtattataa     1500

ctatccgtgg acgttcggac ctggcaccaa gctggaaatc aaacggagca gcgagcagaa     1560

gctgatcagc gaggaggacc tgtagcctga gg                                   1592


<210>  6
<211>  522
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  bispecific T-cell engager with single-chain antibody recognition 
       domains for PD-L1 and mouse CD3

<400>  6

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 
1               5                   10                  15      


Gly Ser Thr Gly Asp Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu 
            20                  25                  30          


Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln 
        35                  40                  45              


Asp Val Ser Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 
    50                  55                  60                  


Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro 
65                  70                  75                  80  


Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
                85                  90                  95      


Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr 
            100                 105                 110         


Leu Tyr His Pro Ala Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
        115                 120                 125             


Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
    130                 135                 140                 


Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
145                 150                 155                 160 


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser 
                165                 170                 175     


Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
            180                 185                 190         


Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
        195                 200                 205             


Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 
    210                 215                 220                 


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
225                 230                 235                 240 


Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
                245                 250                 255     


Leu Val Thr Val Ser Ala Leu Ser Ser Gly Gly Gly Gly Ser Glu Val 
            260                 265                 270         


Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Lys Ser Leu 
        275                 280                 285             


Lys Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Gly Tyr Gly Met 
    290                 295                 300                 


His Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Ser Val Ala Tyr 
305                 310                 315                 320 


Ile Thr Ser Ser Ser Ile Asn Ile Lys Tyr Ala Asp Ala Val Lys Gly 
                325                 330                 335     


Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Leu Leu Phe Leu Gln 
            340                 345                 350         


Met Asn Ile Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg 
        355                 360                 365             


Phe Asp Trp Asp Lys Asn Tyr Trp Gly Gln Gly Thr Met Val Thr Val 
    370                 375                 380                 


Ser Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
385                 390                 395                 400 


Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Pro Ala Ser 
                405                 410                 415     


Leu Gly Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Gln Asp Ile Ser 
            420                 425                 430         


Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu 
        435                 440                 445             


Leu Ile Tyr Tyr Thr Asn Lys Leu Ala Asp Gly Val Pro Ser Arg Phe 
    450                 455                 460                 


Ser Gly Ser Gly Ser Gly Arg Asp Ser Ser Phe Thr Ile Ser Ser Leu 
465                 470                 475                 480 


Glu Ser Glu Asp Ile Gly Ser Tyr Tyr Cys Gln Gln Tyr Tyr Asn Tyr 
                485                 490                 495     


Pro Trp Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys Arg Ser Ser 
            500                 505                 510         


Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 
        515                 520         


<210>  7
<211>  1616
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  bispecific T-cell engager with single-chain antibody recognition 
       domains for PD-L1 and human CD3

<400>  7
ccttaggcgc gccaccatgg agacagacac actcctgcta tgggtactgc tgctctgggt       60

tccaggttcc actggtgacg acatccaaat gacccagagt ccatctagtc tgtctgcttc      120

ggtaggtgat agggtcacta ttacttgcag ggcctcccag gacgtgtcaa ctgcagtggc      180

ttggtaccaa cagaagcccg ggaaagctcc caaactgctg atctactccg ccagctttct      240

gtattccgga gttccgtcta gattttccgg atcaggaagc ggcacggatt tcacactcac      300

aataagcagc ctacaaccag aggacttcgc aacctactat tgtcaacagt acctgtacca      360

tccagccacc tttgggcagg gcaccaaggt ggaaatcaag cgcggtggtg gtggatcagg      420

tggaggcgga agtggaggtg gcggatccga agttcagctt gtcgagtccg gtggcggcct      480

ggttcagcct ggtgggtctt tgcgtctgtc atgcgccgcc tctggtttca ccttttcaga      540

ctcttggatc cactgggtga gacaggcccc aggaaagggt cttgagtggg ttgcatggat      600

tagcccctac ggcggcagta catattacgc ggatagcgtg aaagggaggt ttaccatcag      660

cgcagacacg tcgaagaaca ccgcatacct ccagatgaat tccctccgag ccgaagatac      720

cgccgtgtac tattgtgctc gccggcattg gcctggcggc ttcgattatt ggggacaggg      780

aactctagta acagtgtcgg ccctcagcag cggcggcggc ggcagccagg tgcagctgca      840

gcagagcggc gccgagctgg ccaggcccgg cgccagcgtg aagatgagct gcaaggccag      900

cggctacacc ttcaccaggt acaccatgca ctgggtgaag cagaggcccg gccagggcct      960

ggagtggatc ggctacatca accccagcag gggctacacc aactacaacc agaagttcaa     1020

ggacaaggcc accctgacca ccgacaagag cagcagcacc gcctacatgc agctgagcag     1080

cctgaccagc gaggacagcg ccgtgtacta ctgcgccagg tactacgacg accactactg     1140

cctggactac tggggccagg gcaccaccct gaccgtgagc agcgccggcg gcggcggcag     1200

cggcggcggc ggcagcggcg gcggcggcag ccagatcgtg ctgacccaga gccccgccat     1260

catgagcgcc agccccggcg agaaggtgac catgacctgc agcgccagca gcagcgtgag     1320

ctacatgaac tggtaccagc agaagagcgg caccagcccc aagaggtgga tctacgacac     1380

cagcaagctg gccagcggcg tgcccgccca cttcaggggc agcggcagcg gcaccagcta     1440

cagcctgacc atcagcggca tggaggccga ggacgccgcc acctactact gccagcagtg     1500

gagcagcaac cccttcacct tcggcagcgg caccaagctg gagatcaaca gggccgacac     1560

cgcccccacc agcagcgagc agaagctgat cagcgaggag gacctgtagc ctgagg         1616


<210>  8
<211>  530
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  bispecific T-cell engager with single-chain antibody recognition 
       domains for PD-L1 and human CD3

<400>  8

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 
1               5                   10                  15      


Gly Ser Thr Gly Asp Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu 
            20                  25                  30          


Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln 
        35                  40                  45              


Asp Val Ser Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala 
    50                  55                  60                  


Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro 
65                  70                  75                  80  


Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 
                85                  90                  95      


Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr 
            100                 105                 110         


Leu Tyr His Pro Ala Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 
        115                 120                 125             


Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
    130                 135                 140                 


Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
145                 150                 155                 160 


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser 
                165                 170                 175     


Trp Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
            180                 185                 190         


Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
        195                 200                 205             


Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 
    210                 215                 220                 


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
225                 230                 235                 240 


Ala Arg Arg His Trp Pro Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr 
                245                 250                 255     


Leu Val Thr Val Ser Ala Leu Ser Ser Gly Gly Gly Gly Ser Gln Val 
            260                 265                 270         


Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val 
        275                 280                 285             


Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met 
    290                 295                 300                 


His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr 
305                 310                 315                 320 


Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp 
                325                 330                 335     


Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln 
            340                 345                 350         


Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg 
        355                 360                 365             


Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr 
    370                 375                 380                 


Leu Thr Val Ser Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
385                 390                 395                 400 


Gly Gly Gly Gly Ser Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met 
                405                 410                 415     


Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser 
            420                 425                 430         


Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro 
        435                 440                 445             


Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala 
    450                 455                 460                 


His Phe Arg Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser 
465                 470                 475                 480 


Gly Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser 
                485                 490                 495     


Ser Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Asn Arg 
            500                 505                 510         


Ala Asp Thr Ala Pro Thr Ser Ser Glu Gln Lys Leu Ile Ser Glu Glu 
        515                 520                 525             


Asp Leu 
    530 


